New clinical trial results show that drug combination may up the length of survival for patients with recurrent ovarian cancer. This is the first ovarian cancer study to use a combination of drugs that could be taken orally. The drugs were tested in a phase I combination study followed by a randomized phase 2 trial sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health. The trial compared the activity of the combination of the drug olaparib, ...
Read More
You have just read an article categorized health
titled Drug Combination May Be Highly Effective in Recurrent Ovarian Cancer, Says Study.
Written by:
editor -
Monday, June 2, 2014
There are currently no comments for "Drug Combination May Be Highly Effective in Recurrent Ovarian Cancer, Says Study"
Post a Comment